Flawless clinical profiles cannot salvage a drug from manufacturing facility failures.
Even when therapeutic candidates demonstrate stellar clinical safety and efficacy, the FDA will block approval based entirely on quality control and facility deficiencies at manufacturing partners.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
A highly anticipated biological gout therapy was rejected strictly due to contract manufacturing facility CMC deficiencies rather than its clinical performance.
General facility violations at a contract manufacturer led to an FDA rejection of a clinically sound smoking cessation drug.
A flawless clinical package was held back from approval due solely to uninspected, unresolved facility errors at a third-party manufacturer.
An otherwise flawless oncology drug candidate was rejected entirely due to CMC and third-party facility manufacturing issues.
The FDA rejected the leukemia drug candidate entirely due to GMP compliance failures at a third-party contract manufacturer, ignoring its clean clinical profile.
The FDA issued a Complete Response Letter rejecting the drug entirely due to third-party facility and manufacturing compliance issues, despite acceptable clinical safety and efficacy.
Outstanding facility compliance issues at a contract manufacturer triggered a fourth rejection, bypassing the drug's solid clinical data.
Despite robust clinical survival data, the therapy was rejected a third time solely due to quality compliance issues at the partner's manufacturing facility.
Deficiencies at a contract manufacturing facility forced the company to completely withdraw its European regulatory application despite strong clinical data.